SCOTT AND WHITE MEMORIAL HOSPITAL
- Type
- Teaching hospital
- Where
- Temple, TX
- Medicare CCN
- 450054
- Received
- $1,219,812 in 328 records, 2019 ($55,007 general, $1,164,804 research)
- Source
- CMS Open Payments search ↗
On this site
- Business registration: SCOTT & WHITE MEMORIAL HOSPITAL Fuzzy (name and state)
- Nonprofit contractor: Scott & White Memorial Hospital Fuzzy (name and state)
- Federal award recipient: SCOTT & WHITE MEMORIAL HOSPITAL Fuzzy (name and state)
- Nonprofit: SCOTT & WHITE MEMORIAL HOSPITAL Fuzzy (name and state)
- Patent assignee: Scott & White Memorial Hospital Fuzzy (name and state)
By year
| Program year | Kind | Records | Amount |
|---|---|---|---|
| 2019 | General payment | 38 | $55,007 |
| 2019 | Research payment | 290 | $1,164,804 |
By company
By nature of payment
| Nature | Records | Amount |
|---|---|---|
| Research payment | 290 | $1,164,804 |
| Education | 11 | $19,153 |
| Grant | 2 | $15,000 |
| Space rental or facility fees (teaching hospital only) | 5 | $9,200 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a v | 16 | $4,979 |
| Charitable Contribution | 1 | $4,253 |
| Food and Beverage | 2 | $2,097 |
| Gift | 1 | $324 |
Records
| Date | Company | Amount | Nature | Form | Product | Study | Year |
|---|---|---|---|---|---|---|---|
| 2019-12-31 | Masimo Corporation | $7,499 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2019 | |
| 2019-12-31 | Masimo Corporation | $1,851 | Education | In-kind items and services | EMMA and ISA Device, Devices | 2019 | |
| 2019-12-31 | Masimo Corporation | $1,004 | Education | In-kind items and services | rainbow Acoustic Monitoring Device, Devices | 2019 | |
| 2019-12-31 | Zimmer Biomet Holdings, Inc. | $324 | Gift | In-kind items and services | Zimmer Biomet Instruments and Implants Device, General | 2019 | |
| 2019-12-31 | Masimo Corporation | $183 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-12-25 | Medical Device Business Services, Inc. | $180 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | MEN-15-001 A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implant | 2019 |
| 2019-12-20 | Siemens Medical Solutions USA, Inc. | $47,797 | Research payment | Cash or cash equivalent | Plasma Protein Reagents/Test Kit/Clinical Utilization Device, DX - Diagnostics incl. all products and services | Sample collection for N Latex FLC kappa and lambda | 2019 |
| 2019-12-12 | Merck Sharp & Dohme LLC | $16,500 | Research payment | Cash or cash equivalent | MK-7339 Drug, ONCOLOGY | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Beva | 2019 |
| 2019-12-12 | Merck Sharp & Dohme LLC | $4,984 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-12-10 | PFIZER INC. | $4,968 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2019 | |
| 2019-12-10 | Incyte Corporation | $1,688 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Pre | 2019 | |
| 2019-12-10 | Incyte Corporation | $1,300 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Pre | 2019 | |
| 2019-12-09 | Premia Spine, Ltd. | $3,997 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2019 |
| 2019-12-09 | Incyte Corporation | $57 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-12-09 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-12-09 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-12-06 | Merck Sharp & Dohme LLC | $1,874 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-12-06 | Merck Sharp & Dohme LLC | $1,000 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-12-03 | Merck Sharp & Dohme LLC | $1,421 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-12-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-29 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-11-29 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-11-29 | Genentech, Inc. | $1,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-11-20 | Masimo Corporation | $2,563 | Education | In-kind items and services | Patient SafetyNet System Device, Devices | 2019 | |
| 2019-11-20 | Masimo Corporation | $1,760 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-11-20 | Masimo Corporation | $1,169 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-11-20 | Incyte Corporation | $1,000 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-20 | Masimo Corporation | $158 | Education | In-kind items and services | SET and rainbow SET Device, Devices | 2019 | |
| 2019-11-19 | GlaxoSmithKline, LLC. | $455 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2019 |
| 2019-11-18 | Merck Sharp & Dohme LLC | $37,891 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-11-12 | Merck Sharp & Dohme LLC | $5,322 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-11-12 | Merck Sharp & Dohme LLC | $3,771 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-11-11 | Genentech, Inc. | $800 | Research payment | Cash or cash equivalent | Herceptin Biological, BioOncology | PERTAIN PERTU TRASTU AI 1ST LINE HER2 MBC | 2019 |
| 2019-11-08 | Incyte Corporation | $64 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $30 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $24 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $22 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $10 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $8 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $5 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $5 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $2 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-08 | Incyte Corporation | $1 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-11-06 | Premia Spine, Ltd. | $800 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2019 |
| 2019-11-05 | Merck Sharp & Dohme LLC | $9,328 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-11-04 | Actelion Pharmaceuticals, Ltd | $3,927 | Research payment | Cash or cash equivalent | OPSUMIT Drug, CARDIOVASCULAR DISORDERS | OPUS - AC-055-503 | 2019 |
| 2019-11-04 | Merck Sharp & Dohme LLC | $2,260 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-11-04 | BTG International Inc. | $2,000 | Food and Beverage | Cash or cash equivalent | CROFAB Drug, ANTI-VENOM | 2019 | |
| 2019-11-04 | Actelion Pharmaceuticals, Ltd | $300 | Research payment | Cash or cash equivalent | OPSUMIT Drug, CARDIOVASCULAR DISORDERS | OPUS - AC-055-503 | 2019 |
| 2019-11-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-10-30 | Celgene Corporation | $3,897 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Connect Myeloid: The Myelofibrosis (MF), Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Regist | 2019 |
| 2019-10-30 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | P10-262 | 2019 |
| 2019-10-28 | Merck Sharp & Dohme LLC | $4,364 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-10-25 | Incyte Corporation | $13,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 | |
| 2019-10-25 | Incyte Corporation | $4,000 | Research payment | Cash or cash equivalent | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 | |
| 2019-10-25 | Incyte Corporation | $2,566 | Research payment | Cash or cash equivalent | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 | |
| 2019-10-25 | Incyte Corporation | $1,500 | Research payment | Cash or cash equivalent | A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With | 2019 | |
| 2019-10-24 | PFIZER INC. | $10,431 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2019 | |
| 2019-10-24 | Intuitive Surgical, Inc. | $950 | Education | In-kind items and services | Da Vinci Surgical System Device, SURGERY | 2019 | |
| 2019-10-24 | PFIZER INC. | $500 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2019 | |
| 2019-10-24 | Merck Sharp & Dohme LLC | $75 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-10-23 | ABBVIE INC. | $500 | Research payment | Cash or cash equivalent | Humira Biological, Immunology | P10-262 | 2019 |
| 2019-10-22 | KCI USA, Inc. | $2,000 | Education | In-kind items and services | VAC ULTA Device, DEVICES | 2019 | |
| 2019-10-21 | GlaxoSmithKline, LLC. | $885 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2019 |
| 2019-10-17 | Premia Spine, Ltd. | $1,872 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2019 |
| 2019-10-16 | Merck Sharp & Dohme LLC | $1,376 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-10-15 | Celgene Corporation | $4,420 | Research payment | Cash or cash equivalent | Revlimid Drug, Hematology / Oncology | Connect MM- The Multiple Myeloma Disease Registry (OS002982) | 2019 |
| 2019-10-10 | Incyte Corporation | $250 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-10-09 | Stryker Corporation | $889 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $439 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $105 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-09 | Stryker Corporation | $30 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-10-07 | Merck Sharp & Dohme LLC | $32,478 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-10-03 | Merck Sharp & Dohme LLC | $10,607 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-10-01 | Incyte Corporation | $14,000 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-10-01 | Incyte Corporation | $5,500 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-10-01 | Incyte Corporation | $2,600 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-10-01 | Incyte Corporation | $2,000 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-10-01 | Incyte Corporation | $1,400 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-10-01 | Incyte Corporation | $95 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignanc | 2019 | |
| 2019-09-26 | Zimmer Biomet Holdings, Inc. | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | Traumaone Device, CMF & Thoracic | 2019 | |
| 2019-09-25 | CSL Behring | $11 | Education | In-kind items and services | Zemaira Biological, Pulmonary/Respiratory Diseases | 2019 | |
| 2019-09-23 | Merck Sharp & Dohme LLC | $89 | Research payment | In-kind items and services | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-09-20 | Merck Sharp & Dohme LLC | $12,153 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-09-17 | Merck Sharp & Dohme LLC | $1,521 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-09-16 | Boehringer Ingelheim International GmbH | $2,027 | Research payment | Cash or cash equivalent | Crohn's Disease Ph III study | 2019 | |
| 2019-09-10 | Incyte Corporation | $71 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $28 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $28 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $28 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $25 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $19 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $19 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $19 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $17 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $14 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $14 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $14 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-10 | Incyte Corporation | $14 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-09 | Merck Sharp & Dohme LLC | $10,826 | Research payment | In-kind items and services | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-09-06 | Incyte Corporation | $1,250 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-09-05 | Premia Spine, Ltd. | $3,744 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2019 |
| 2019-09-03 | Merck Sharp & Dohme LLC | $43,304 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-09-03 | Premia Spine, Ltd. | $1,300 | Research payment | Cash or cash equivalent | TOPS | A Clinical Study to Assess the Safety and Effectiveness of the Premia Spine TOPS System | 2019 |
| 2019-09-02 | Merck Sharp & Dohme LLC | $227 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-08-30 | Merck Sharp & Dohme LLC | $250 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-08-26 | Boehringer Ingelheim International GmbH | $79 | Research payment | In-kind items and services | Crohn's Disease Ph III study | 2019 | |
| 2019-08-26 | Boehringer Ingelheim International GmbH | $1 | Research payment | In-kind items and services | Crohn's Disease Ph III study | 2019 | |
| 2019-08-23 | Merck Sharp & Dohme LLC | $4,616 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-08-22 | Merck Sharp & Dohme LLC | $812 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-08-22 | Merck Sharp & Dohme LLC | $118 | Research payment | In-kind items and services | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-08-22 | Merck Sharp & Dohme LLC | $75 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-08-22 | Merck Sharp & Dohme LLC | $50 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-08-21 | GlaxoSmithKline, LLC. | $500 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2019 |
| 2019-08-21 | GlaxoSmithKline, LLC. | $64 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2019 |
| 2019-08-19 | CSL Behring | $2,000 | Space rental or facility fees (teaching hospital only) | Cash or cash equivalent | 2019 | ||
| 2019-08-15 | Merck Sharp & Dohme LLC | $14,955 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-08-15 | Merck Sharp & Dohme LLC | $11,615 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-08-15 | GlaxoSmithKline, LLC. | $10,575 | Research payment | Cash or cash equivalent | BENLYSTA Biological, IMMUNOLOGY | A 5-YEAR PROSPECTIVE OBSERVATIONAL REGISTRY TO ASSESS ADVERSE EVENTS O | 2019 |
| 2019-08-08 | Medical Device Business Services, Inc. | $1,000 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | MEN-15-001 A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implant | 2019 |
| 2019-08-08 | Incyte Corporation | $49 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Pre | 2019 | |
| 2019-08-07 | Medtronic Vascular, Inc. | $2,808 | Research payment | Cash or cash equivalent | Aptus Heli-FX Device, Aortic EndoAnchors | ANCHOR Registry | 2019 |
| 2019-08-06 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-08-06 | Genentech, Inc. | $1,243 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-08-05 | Actelion Pharmaceuticals, Ltd | $1,345 | Research payment | Cash or cash equivalent | OPSUMIT Drug, CARDIOVASCULAR DISORDERS | OPUS - AC-055-503 | 2019 |
| 2019-08-05 | Incyte Corporation | $250 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-08-05 | Boehringer Ingelheim International GmbH | $150 | Research payment | Cash or cash equivalent | Crohn's Disease Ph III study | 2019 | |
| 2019-07-29 | Siemens Medical Solutions USA, Inc. | $101,675 | Research payment | Cash or cash equivalent | Atellica UAS 800 Analyzer Clinical Trial Protocol-External Site testing | 2019 | |
| 2019-07-29 | Merck Sharp & Dohme LLC | $15,100 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-07-29 | Merck Sharp & Dohme LLC | $10,826 | Research payment | In-kind items and services | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-07-23 | Merck Sharp & Dohme LLC | $32,042 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-07-16 | Stryker Corporation | $941 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $324 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Boehringer Ingelheim International GmbH | $150 | Research payment | Cash or cash equivalent | Crohn's Disease Ph III study | 2019 | |
| 2019-07-16 | Stryker Corporation | $120 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-16 | Stryker Corporation | $31 | Compensation for services other than consulting, including serving as faculty or as a speaker at a v | Cash or cash equivalent | REPROCESSED DEVICE Device, HYGIA HEALTH SERVICES | 2019 | |
| 2019-07-11 | Boehringer Ingelheim International GmbH | $4,000 | Research payment | Cash or cash equivalent | Crohn's Disease Ph III study | 2019 | |
| 2019-07-11 | Boehringer Ingelheim International GmbH | $772 | Research payment | Cash or cash equivalent | Crohn's Disease Ph III study | 2019 | |
| 2019-07-10 | Merck Sharp & Dohme LLC | $148 | Research payment | In-kind items and services | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-07-09 | Merck Sharp & Dohme LLC | $3,100 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-07-09 | Merck Sharp & Dohme LLC | $2,900 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-07-08 | Merck Sharp & Dohme LLC | $170 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-07-05 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2019 | |
| 2019-07-03 | Medical Device Business Services, Inc. | $55 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | MEN-15-001 A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implant | 2019 |
| 2019-07-03 | Medical Device Business Services, Inc. | $55 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | MEN-15-001 A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implant | 2019 |
| 2019-07-02 | Merck Sharp & Dohme LLC | $262 | Research payment | In-kind items and services | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-07-01 | Merck Sharp & Dohme LLC | $43,304 | Research payment | In-kind items and services | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-07-01 | Incyte Corporation | $453 | Research payment | Cash or cash equivalent | A Phase 12, Open Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and INCB039110 in Subjects With Pre | 2019 | |
| 2019-06-27 | Stryker Corporation | $500 | Research payment | Cash or cash equivalent | TRIATHLON Device, KNEES | TRIATHLON CRUCIATE RETAINING CR TOTAL KNEE SYSTEM OUTCOMES STUDY | 2019 |
| 2019-06-26 | Medtronic Vascular, Inc. | $10,000 | Grant | Cash or cash equivalent | 2019 | ||
| 2019-06-25 | Merck Sharp & Dohme LLC | $14,956 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-06-25 | Merck Sharp & Dohme LLC | $6,008 | Research payment | Cash or cash equivalent | KEYTRUDA Biological, ONCOLOGY | A Phase 1b Multi-cohort Study of the Combination of PembrolizumabMK-3475 plus Binimetinib alone or the Combination of Pe | 2019 |
| 2019-06-24 | Merck Sharp & Dohme LLC | $611 | Research payment | In-kind items and services | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-06-20 | Stryker Corporation | $500 | Research payment | Cash or cash equivalent | TRIATHLON Device, KNEES | TRIATHLON CRUCIATE RETAINING CR TOTAL KNEE SYSTEM OUTCOMES STUDY | 2019 |
| 2019-06-12 | Merck Sharp & Dohme LLC | $2,489 | Research payment | Cash or cash equivalent | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
| 2019-06-12 | OXFORD GENE TECHNOLOGY INC | $97 | Food and Beverage (6 payments) | In-kind items and services | 2019 | ||
| 2019-06-06 | Genentech, Inc. | $21,458 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-06-06 | Genentech, Inc. | $8,721 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-06-06 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-06-06 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-06-06 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-06-06 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-06-06 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-06-06 | Genentech, Inc. | $2,000 | Research payment | Cash or cash equivalent | Rituxan Biological, BioOncology/Immunology | OBINUTUZUMAB GAZYVA POLATUZUMAB VEDOTIN VENETOCLAX GDC 0199 IN RR FL DLBCL | 2019 |
| 2019-06-06 | PFIZER INC. | $1,000 | Research payment | Cash or cash equivalent | A PHASE 2B RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF STAPHYLOCOCCUS AUREUS 4 | 2019 | |
| 2019-06-04 | Medical Device Business Services, Inc. | $578 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | MEN-15-001 A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implant | 2019 |
| 2019-06-04 | Medical Device Business Services, Inc. | $578 | Research payment | Cash or cash equivalent | MemoryGel Breast Implants Device, Plastic Surgery | MEN-15-001 A Study of the Safety and Effectiveness of the Mentor Larger Size MemoryGel Ultra High Profile Breast Implant | 2019 |
| 2019-06-04 | Incyte Corporation | $250 | Research payment | Cash or cash equivalent | A Phase 2, Open Label, Single Agent, Multicenter Study to Evaluate the Efficacy and Safety of INCB054828 in Subjects Wit | 2019 | |
| 2019-06-03 | Merck Sharp & Dohme LLC | $10,826 | Research payment | In-kind items and services | SCH 417690-- VICRIVIROC Drug, INFECTIOUS DISEASE | A Phase II study to evaluate the safety and efficacy of Vicriviroc MK-7690 in combination with Pembrolizumab MK-3475 in | 2019 |
The latest 200 records of 328.
CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.
The area Census
County outline, the place (blue), the tract (orange) and the ZIP center (dot).
In Temple, TX, county Bell County, TX, state Texas; placed by its city name.
| Measure | Place (city or town) Temple, TX | County Bell County, TX | State Texas |
|---|---|---|---|
| Population B01003 | 89,602 | 386,897 | 30,188,424 |
| Population, 2020 census P1 | 82,073 | 370,647 | 29,145,505 |
| Median age B01002 | 33.8 | 32.3 | 35.6 |
| Under 18 B01001 | 26.6% | 27.5% | 25.0% |
| 65 and over B01001 | 15.1% | 11.9% | 13.4% |
| Households B11001 | 34,514 | 142,305 | 10,992,816 |
| Foreign born B05002 | 8.2% | 8.6% | 17.6% |
| Median household income B19013 | $68,204 | $68,865 | $78,476 |
| Median family income B19113 | $86,005 | $81,043 | $94,599 |
| Per capita income B19301 | $34,319 | $34,279 | $40,752 |
| Poverty rate B17001 | 16.0% | 14.5% | 13.8% |
| Unemployment rate B23025 | 6.6% | 6.8% | 5.3% |
| Civilian labor force B23025 | 42,457 | 170,572 | 15,233,563 |
| Mean commute (minutes) B08013 | 21.0 | 23.9 | 26.7 |
| Bachelor's degree or higher B15003 | 30.6% | 27.2% | 33.8% |
| Housing units B25001 | 37,299 | 155,018 | 12,128,515 |
| Owner-occupied B25003 | 52.3% | 56.5% | 62.6% |
| Renters B25003 | 47.7% | 43.5% | 37.4% |
| Median home value B25077 | $239,000 | $241,000 | $283,800 |
| Median gross rent B25064 | $1,231 | $1,224 | $1,403 |
| White, not Hispanic B03002 | 51.4% | 42.4% | 39.1% |
| Black B03002 | 12.1% | 21.5% | 11.9% |
| Hispanic or Latino B03002 | 29.0% | 26.3% | 39.7% |
| Asian B03002 | 2.0% | 2.9% | 5.5% |
| American Indian and Alaska Native B03002 | 0.1% | 0.1% | 0.1% |
Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Temple, TX.
Comments